Literature DB >> 21076549

Evaluation of Different Preparation Procedures of Pathogen Reduction Technology(Mirasol®)-Treated Platelets Collected by Plateletpheresis.

Karin Janetzko1, Katharina Hinz, Susanne Marschner, Ray Goodrich, Harald Klüter.   

Abstract

SUMMARY:
BACKGROUND: The Mirasol® pathogen reduction technology (PRT) for platelet concentrates (PC) uses riboflavin and UV light (270-360 nm). We evaluated the impact of PRT on platelets in comparison to standard single-donor PC.
MATERIAL AND METHODS: Platelets were resuspended in autologous plasma. After 2 h rest without agitation, PC were split into an untreated control unit (C-PC) and an immediately treated unit (T-PC) (series I). In series IV, split PC were stored under agitation over night before PRT was carried out. Platelet quality was assessed by pH, glucose consumption, lactate production rate, LDH, soluble sCD62p and CD62p expression with and without TRAP (thrombin receptor-activating peptide) over 7 days.
RESULTS: SERIES I: On day 5, pH values were lower for T-PC (6.8 ± 0.2 vs. 7.4 ± 0.1, C-PC), accompanied by a higher glucose consumption rate of 0.069 ± 0.016 vs. 0.035 ± 0.006 mmol/10(12) platelets/h and lactate production rate of 0.126 ± 0.031 vs. 0.063 ± 0.011 mmol/10(12) platelets/h. CD62p using TRAP was lower for T-PC (50 ± 11 vs. 62 ± 14%). Baseline activation was higher in T-PC (35 ± 12 vs. 28 ± 15%). Longer initial rest time had no impact on these results (series II/III/IV).
CONCLUSION: PRT leads to an increase of platelet metabolism and activation independent of the length of the initial rest times. PC resuspended in autologous plasma should be stored at maximum up to day 5.

Entities:  

Year:  2009        PMID: 21076549      PMCID: PMC2969128          DOI: 10.1159/000230038

Source DB:  PubMed          Journal:  Transfus Med Hemother        ISSN: 1660-3796            Impact factor:   3.747


  22 in total

1.  Decreased responsiveness and development of activation markers of PLTs stored in plasma.

Authors:  Joyce Curvers; Elisabeth C M van Pampus; Marion A H Feijge; Eva Rombout-Sestrienkova; Peter L A Giesen; Johan W M Heemskerk
Journal:  Transfusion       Date:  2004-01       Impact factor: 3.157

2.  Role of platelet surface glycoprotein Ibalpha and P-selectin in the clearance of transfused platelet concentrates.

Authors:  Valery Leytin; David J Allen; Adam Gwozdz; Bernadette Garvey; John Freedman
Journal:  Transfusion       Date:  2004-10       Impact factor: 3.157

3.  Soluble monomeric P-selectin containing only the lectin and epidermal growth factor domains binds to P-selectin glycoprotein ligand-1 on leukocytes.

Authors:  P Mehta; K D Patel; T M Laue; H P Erickson; R P McEver
Journal:  Blood       Date:  1997-09-15       Impact factor: 22.113

4.  Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light.

Authors:  L J Cardo; F J Rentas; L Ketchum; J Salata; R Harman; W Melvin; P J Weina; J Mendez; H Reddy; R Goodrich
Journal:  Vox Sang       Date:  2006-02       Impact factor: 2.144

5.  In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function.

Authors:  A D Michelson; M R Barnard; H B Hechtman; H MacGregor; R J Connolly; J Loscalzo; C R Valeri
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

6.  Differential induction of P-selectin expression on platelets by two cell separators during plateletpheresis and the effect of gender on the release of soluble P-selectin.

Authors:  P Stohlawetz; N Hergovich; G Stiegler; H G Eichler; P Höcker; S Kapiotis; B Jilma
Journal:  Transfusion       Date:  1998-01       Impact factor: 3.157

7.  Photosensitized inactivation of ribonucleic acids in the presence of riboflavin.

Authors:  A Tsugita; Y Okada; K Uehara
Journal:  Biochim Biophys Acta       Date:  1965-06-08

8.  PADGEM protein: a receptor that mediates the interaction of activated platelets with neutrophils and monocytes.

Authors:  E Larsen; A Celi; G E Gilbert; B C Furie; J K Erban; R Bonfanti; D D Wagner; B Furie
Journal:  Cell       Date:  1989-10-20       Impact factor: 41.582

9.  Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates.

Authors:  S Perez-Pujol; R Tonda; M Lozano; B Fuste; I Lopez-Vilchez; A M Galan; J Li; R Goodrich; G Escolar
Journal:  Transfusion       Date:  2005-06       Impact factor: 3.157

10.  Functional inactivation of white blood cells by Mirasol treatment.

Authors:  Loren D Fast; Gilbert Dileone; Junzhi Li; Raymond Goodrich
Journal:  Transfusion       Date:  2006-04       Impact factor: 3.157

View more
  3 in total

1.  Haemostatic profile of riboflavin-treated apheresis platelet concentrates.

Authors:  Eleni Petrou; Georgios K Nikolopoulos; Anastasios G Kriebardis; Katerina Pantavou; Electra Loukopoulou; Andreas G Tsantes; Hara T Georgatzakou; Eirini Maratou; Evdoxia Rapti; Sofia Mellou; Styliani Kokoris; Argyri Gialeraki; Argirios E Tsantes
Journal:  Blood Transfus       Date:  2021-05-21       Impact factor: 5.752

Review 2.  Redox Proteomics and Platelet Activation: Understanding the Redox Proteome to Improve Platelet Quality for Transfusion.

Authors:  Giona Sonego; Mélanie Abonnenc; Jean-Daniel Tissot; Michel Prudent; Niels Lion
Journal:  Int J Mol Sci       Date:  2017-02-11       Impact factor: 5.923

Review 3.  Impact of different pathogen reduction technologies on the biochemistry, function, and clinical effectiveness of platelet concentrates: An updated view during a pandemic.

Authors:  Gines Escolar; Maribel Diaz-Ricart; Jeffrey McCullough
Journal:  Transfusion       Date:  2021-12-06       Impact factor: 3.337

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.